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Abstract
The search for drugs with anorectic activity, acting within the adrenergic system has
attracted the interest of researchers. Partial α2-adrenoceptor agonists might offer the poten-
tial for effective and safe treatment of obesity. We compared the effectiveness and safety of
α2-adrenoceptor ligands in reducing body mass. We also analyzed if antagonist and partial
agonists of α2-adrenoceptor––yohimbine and guanfacine––act similarly, and determined
which course of action is connected with anorectic activity. We tested intrinsic activity and
effect on the lipolysis of these compounds in cell cultures, evaluated their effect on meal
size, body weight in Wistar rats with high-fat diet-induced obesity, and determined their
effect on blood pressure, heart rate, lipid profile, spontaneous locomotor activity, core tem-
perature and glucose, as well as glycerol and cortisol levels. Both guanfacine and yohim-
bine showed anorectic activity. Guanfacine was much more effective than yohimbine. Both
significantly reduced the amount of intraperitoneal adipose tissue and had a beneficial
effect on lipid profiles. Decreased response of α2A-adrenoceptors and partial stimulation of
α2B-receptors seem to be responsible for the anorectic action of guanfacine. The stimulation
of α1-adrenoceptors by guanfacine is responsible for cardiovascular side effects but may
also be linked with improved anorexic effect. α1-adrenoceptor blockade is connected with
the side effects of yohimbine, but it is also associated with the improvement of lipid profiles.
Guanfacine has been approved by the Food and Drug Administration (FDA) to treat hyper-
tension and conduct disorder, but as it reduces body weight, it is worth examining its effec-
tiveness and safety in models of obesity.
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Introduction
Obesity is affecting an increasing number of individuals in the human population [1]. It is esti-
mated that over one billion people in the world of adults are overweight, and that obesity
affects about 312 million of these people [2]. The World Health Organization has recognized
obesity as an epidemic of the 21st century. Obese people more frequently suffer from cardio-
vascular diseases, diabetes, and diseases of the digestive system, and are at higher risk of devel-
oping cancer [3]. This shows the importance of conducting research leading to the discovery of
a drug that will effectively reduce weight.
The idea to use α2-adrenoceptor antagonists, such as yohimbine, in the treatment of obesity
has been considered by many researchers [4, 5]. However, their side effects were unacceptable
and their effectiveness was insufficient. Yohimbine, a well-known α2-adrenoceptor antagonist,
has an undesirable effect on blood pressure and heart rate [4, 6, 7], due to its effect on both cen-
tral and peripheral adrenoceptors. Moreover, the higher doses of this drug, which were used
for weight reduction, affected α1-adrenoreceptors as well. Since yohimbine at such doses can
block both postsynaptic α1- and α2-adrenoceptors present in arterial vessels, there is a risk of a
very significant drop in blood pressure.
In recent years, an increasing number of reports in the literature have suggested that the
effectiveness of drugs such as sibutramine or bupropion in reducing weight is associated with
the effect on α2-adrenoceptors [8, 9]. Therefore, inverse α2-adrenoceptor agonists may be use-
ful in the treatment of obesity [9]. It is not surprising though that compounds possessing ano-
rectic activity and acting within the adrenergic system have attracted the interest of
researchers.
Guanfacine is a selective agonist of α2-adrenoceptors [10, 11], which in many experimental
models acts differently than other agonists, e.g. clonidine [12, 13]. To the best of our knowl-
edge, there are no studies in the literature concerning the anorectic effect of guanfacine in obe-
sity models.
Guanfacine has been approved by Food and Drug Administration (FDA) to treat hyperten-
sion, and lately to treat conduct disorder in children and adolescents. As it shows weight reduc-
ing properties, we decided to examine its efficacy and safety in models of obesity and
determine if it could be safely used in obese patients without clear cardiovascular problems.
Consequently, we have undertaken studies to determine the activity and safety of guanfacine
in an experimental model of obesity in rats, analyzed its effect on α2-adrenoceptors and investi-
gated which subtype of these receptors is most involved in reducing weight after chronic
treatment.
In this paper, we compare the effectiveness of the anorexic action and safety of yohim-
bine––an α2-adrenoceptor antagonist––and guanfacine––a partial agonist of α2-adrenocep-
tor––in rats with diet-induced obesity and determine their effect on core temperature, blood
pressure, heart rate and lipid and carbohydrate profiles, as well as glycerol and cortisol levels.
We also compare their effect on the adrenoceptors, including α2-adrenoceptors subtypes.
Moreover, we determine the effect of guanfacine on spontaneous activity and its lipolytic
effect.
Materials and Methods
Drugs
Guanfacine, oxymetazoline, brimonidine, clonidine (Sigma-Aldrich, Germany), yohimbine
(Tocris, Bristol, UK), heparin (Polfa Warszawa S.A., Warsaw, Poland), and thiopental (Sandoz
International, France).
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Animals
The experiments were carried out on male Wistar rats (initial body weight 140–160 g, eight
weeks of age, in the growth phase). The animals were housed in pairs in plastic cages in con-
stant temperature facilities exposed to 12–12 light-dark cycle, water and food were available ad
libitum. Control and experimental groups consisted of six to eight animals each. All experi-
ments were conducted according to the guidelines of the Animal Use and Care Committee of
the Jagiellonian University and were approved for realization (2012 and 2015; Poland; Permis-
sion No 54/2012 and 17/2015). All surgery was performed under thiopental anesthesia, and
every effort was made to minimize suffering.
Determination of the intrinsic activity of the α2A-adrenoceptor and α2B-
adrenoceptor
Intrinsic assays of cells with stable expression of the α2A-adrenoceptor or α2B-adrenoceptor
were performed using ready-to-use assay kits according the manufacturers' guidelines (Invitro-
gen Life Technologies and Perkin Elmer, respectively). Reference compounds were: brimoni-
dine, oxymethazoline and clonidine.
Obesity induced with a fatty diet and its effect on body weight, food and
water intakes
Male Wistar rats (140–160 g) were pair-housed and fed a fatty diet consisting of 40% fat blend
(Labofeed B with 40% lard, Morawski, Manufacturer Feed, Poland), with water available ad
libitum for 10 weeks. Control rats were fed a standard diet (Labofeed B) for 10 weeks. Diet-
induced obese rats were randomly divided into five equal groups ((the same mean body weight
(b.w.) in each group)), and treated intraperitoneally (i.p.): 2 or 5 mg/kg/day yohimbine or 0.5
or 2 mg/kg/day guanfacine or vehicle (water– 0.3 ml), once daily, between 9:00 AM and 10:00
AM for 30 days. Intakes of food and water, and body weight were measured daily immediately
prior to administration of drugs. On the 31st day, 20 minutes after intraperitoneal administra-
tion of heparin 1000 j/rat and thiopental (70 mg/kg b.w., i.p.), blood was collected from animals
and was centrifuged for 10 minutes at 1500 rpm to separate plasma. Also, intraperitoneal fat
was collected and weighed.
The effect of guanfacine on locomotor activity during chronic treatment
in diet-induced obese rats housed in pairs in home cages
The locomotor activity of rats treated with guanfacine was measured with a special RFID-sys-
tem—TraffiCage (TES-Systems, Germany). The rats were housed in pairs in home cages with
food and water available ad libitum. The animals were subcutaneously implanted with trans-
mitter identification (RFID), which recorded the presence and time spent in different areas of
the cage, and then grouped the data in a special computer program. The rats were treated intra-
peritoneally with guanfacine 2 mg/kg b.w./day or a vehicle—water 0.3 ml/kg (diet-induced
obese-control group), once per day in the morning for 30 days. Locomotor activity was
recorded for 24 hours after administration of the compound.
Determination of the effect on blood pressure in rats after a single
administration
Next, normotensive rats were anesthetized with thiopental (70 mg/kg) by i.p. injection. The left
carotid artery was cannulated with tubing filled with heparin solution in saline to facilitate
pressure measurements using Apparatus PowerLab 4/35 (ADInstruments, Australia). Blood
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pressure was measured: before intraperitoneal administration of guanfacine and yohimbine—
time 0 min (control pressure) and during the next 90 min.
The effect of guanfacine on lipid and carbohydrate profiles and glycerol
levels in diet-induced obese rats
To determine the lipid profile and glucose level in the plasma, standard tests from Biomaxima
S.A. (Poland) were used. To determine the glycerol level in the plasma, a Glycerol Colorimetric
Assay Kit (Cayman, USA) was used.
Effect of guanfacine on cortisol levels in diet-induced obese rats
To determine the cortisol level in the plasma, Cortisol Express EIA Kit (Cayman, USA) was
used.
Determination of lipolysis in vitro
Cell culture and differentiation. The 3T3-L1 cells were obtained from the ATCC (CL-
173). The cells were thawed according to the manufacturer's protocol. 3T3-L1 cells were culti-
vated in Dulbecco's Modified Eagle's Medium (DMEM, ATCC) supplemented with 10% calf
bovine serum (ATCC), 100 IU/ml penicillin (ATCC) and 100 μg/ml streptomycin (ATCC).
The cells were seeded on 48-well culture plates at a density of 50 000 cells per well. To induce
differentiation, 3T3-L1 were cultured for 2 days until a confluence was reached and then the
culture medium was replaced with a fresh induction medium containing 10 μg/ml human
recombinant insulin, 0.5 mM 3-isobutyl-1-methylxanthine and 1 μM dexamethasone. After 2
days, the medium was replaced with a differentiation medium containing 10 μg/ml human
recombinant insulin only. Then, differentiation medium was replaced with a culture medium
without differentiating factors. The culture medium was changed every 2 days. Adipocytes for
experiments were used 18 days after the initiation of differentiation.
Compounds. All compounds were dissolved in dimethyl sulfoxide (DMSO) to obtain
stock concentrations. From the stock solution, dilutions were prepared in phosphate buffered
saline (PBS). The final concentrations of compounds were 50 μM, 10 μM and 1 μM. All experi-
ments were performed in triplicates. The cells were incubated with the tested compounds for
24 hours.
Cell membrane damage. The bioluminescent ToxiLight bioassay (Lonza) is a highly sensi-
tive cytotoxicity assay designed to measure cell membrane damage. After incubation of cells
with the tested compounds, 10 μl of cell supernatant was deposited in a new 96-well plate.
Then, 40 μl of the Adenylate Kinase Detection Reagent (AKDR) was added per well. After 5
minutes of incubation at 22°C, the luminescence intensity was measured in a multifunction
plate reader (POLARstar Omega, BMG Labtech).
Cell viability. Cell viability was measured using PrestoBlue reagent (Life Technologies).
After incubation of cells with the tested compounds, PrestoBlue reagent was added to each well
of a microplate in an amount equal to one tenth of the volume of the remaining medium. After
20 minutes of incubation at 37°C, the fluorescence intensity (EX 530 EM 580 nm) was mea-
sured in the multifunction plate reader (POLARstar Omega, BMG Labtech).
Glucose utilization. An Amplex Red Glucose Kit (Life Technologies) was used to measure
glucose utilization by 3T3-L1 after incubation with the tested compounds. To 10 μl of the
tested sample 10 μl of 200 μMAmplexRed reagent (10-acetyl-3,7-dihydroxyphenoxazine) was
added with 0.4 U/ml peroxidase (HRP), and 4 U/ml of glucose oxidase in 50 mM potassium
phosphate buffer pH 7.4. After 30 minutes of incubation at 37°C, the fluorescence intensity
Alpha2-Adrenoceptor Ligands and Obesity
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(EX 530 EM 580 nm) was measured in the multifunction plate reader (POLARstar Omega,
BMG Labtech).
Lipolysis. Lipolysis was evaluated by measuring the amount of glycerol released into the
medium. The supernatants were collected, and the amount of glycerol was determined using
the AdipoLyze Lipolysis Detection Kit (Lonza) according to the manufacturer’s protocol. After
2 hours of reagent incubation with the tested sample at 22°C, the fluorescence intensity (EX
520 EM 590 nm) was measured in the multifunction plate reader (POLARstar Omega, BMG
Labtech).
Effect of guanfacine and yohimbine on core temperature
Those animals with induced obesity were subcutaneously implanted with a DST micro-HRT
heart rate logger, which simultaneously measured long-term heart rate and core temperature
in the animal (Star Oddi, Island). The temperature was recorded both before and 24 hours
after the intraperitoneal administration of guanfacine at the dose of 2 mg/kg b.w. Mercury soft-
ware was used to collect and analyze the data. On the basis of this technology, measurements
are made without the direct intervention of the researcher, so they do not cause disturbances
evoked by stress in animals.
Statistical analysis
The statistical calculations were carried out with the GraphPad Prism 6 program. Results are
given as arithmetic means with SEM. The statistical significance was calculated using a one-
way ANOVA with Dunnett's Multiple Comparison Test post-hoc or two-way ANOVA (Bon-
ferroni test post-hoc) or Student’s t-test (when two groups were compared). Differences were
considered statistically significant at: P 0.05, P 0.01, and P 0.001.
Results
Intrinsic activity
The potency (pEC50) and intrinsic activity of oxymetazoline, brimonidine, guanfacine, cloni-
dine and yohimbine at human cloned α2-adrenoceptors are shown in Table 1. Guanfacine and
clonidine showed the properties of partial agonists of both α2-adrenoceptors subtypes (A and
B). Guanfacine and clonidine activated subtype A of this receptor in concentrations approxi-
mately 50-fold lower than subtype B. Yohimbine showed antagonistic properties for both sub-
types of α-adrenoceptors.
Obesity induced with fatty diet
After 10 weeks of inducing obesity, the percentage of body weight difference between rats fed
with standard food (control group) and rats fed a fatty diet (diet-induced obesity control
group) was 14.29% (P<0.001). Table 2 shows the baseline body weight and body weight after
10 weeks of food consumption in these groups. Clearly, it can be concluded that obesity in this
model was induced. For the next 30 days, the difference in body weight changes between
groups remained practically unchanged, i.e. 15.82% (P<0.001). Results are shown in Fig 1.
During the induction of obesity, the difference in the amount (g) of food intake between the
two groups––control and diet-induced obesity control––was 17%. An average rat from the
control and diet-induced obesity control group ate 23 g and 19 g of food for 24 hours, respec-
tively. If calculated as the calories obtained from food, the difference was significant, i.e. 63%
(P<0.05). The difference in the amount of water intake was 14.83%. The results are shown in
Table 2.
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PLOS ONE | DOI:10.1371/journal.pone.0141327 October 27, 2015 5 / 20
The effect of guanfacine on body weight in rats with high-fat diet-induced
obesity
After 30 days of treatment with guanfacine at the dose of 0.5 mg/kg b.w./day, the body weight
of rats increased by 2.84% in comparison with the body weight measured before the first
administration of the drug. After 30 days of treatment, the difference in body weight between
the diet-induced obesity control group and the group treated with guanfacine at the dose of 0.5
mg/kg b.w./day was 9.22% (P<0.05), but the differences in body weight changes were signifi-
cant only on the 18th day of treatment. There was no statistical difference between the controls
(receiving standard food) and this tested group after 30 days of treatment. It can be concluded
that guanfacine at this dose showed a minor anorectic activity. The changes in body weight are
shown in Fig 1.
After 30 days of treatment of the obese rats with guanfacine at the dose of 2 mg/kg b.w./day,
the body weight of animals was 15.24% lower than the body weight measured before the first
administration of the drug. After 30 days of treatment, the difference between the body weight
in the diet-induced obesity control group and the group treated with guanfacine at the dose of
2 mg/kg b.w./day was 22.21% (P<0.001). It can be assumed, however, that guanfacine at this
dose possesses a significant anorectic activity. There was no statistically significant difference
between the controls (receiving standard food) and this tested group after 30 days of treatment.
The changes in body weight are shown in Fig 1.
Table 1. Potency (pEC50) and intrinsic activity (relative to full agonist) of tested compounds at human cloned α2-adrenoreceptors.
Compound α2A-adrenoceptor α2B-adrenoceptor
pEC50 I.A. pEC50 I.A.
Brimonidine 8.1 ± 0.05 1 NT NT
Oxymetazoline 7.5 ± 0.02 0.6 ± 0.04 5.5 ± 0.02 1
Guanfacine 7.6 ± 0.03 0.8 ± 0.03 5.6 ± 0.04 0.5 ± 0.04
Clonidine 5.9 ± 0.03 0.7 ± 0.03 4.3 ± 0.21 0.3 ± 0.05
Yohimbine 8.3 ± 0.06 0—antagonist 7.8 ± 0.06 0—antagonist
I.A.–intrinsic activity; NT—not tested. pEC50 and I.A. were determined in functional assays (Tango, AequoScreen). Shown is the mean ± SEM (n = 3).
doi:10.1371/journal.pone.0141327.t001
Table 2. The effect of studied compounds on body weight, food and water intake.
Control Diet-induced obesity control
Initial body weight, g 151.7 ± 5.56 155.6 ± 2.06
Final body weight, g 359.7 ± 6.03 411.1 ± 5.85***
Total food intake, kcal; 4502.4 ± 364.40 7339.4 ± 898.70*
Total food intake, g of food 1608 ± 130.10 1334.4 ± 163.4
Total water intake, ml 2312.5 2013.9
Body weight, food intake, water intake during 10 weeks inducing obesity in Wistar rats on control food or diet-induced obesity, mean on one
individual ± SEM. Treatment: Control group—water, Diet-induced obesity control group—water;
*Significant vs. control group, P<0.05;
***Significant vs. control group, P<0.001.
doi:10.1371/journal.pone.0141327.t002
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Fig 1. The effect of guanfacine (A) and yohimbine (B) on body weight. The change in body weight in control (standard diet) and diet-induced obese
Wistar rats, treated for 30 days with the tested compounds; Control group—water; Diet-induced obesity control group—water; Yohimbine at 2 mg/kg b.w., i.
p.; Yohimbine at 5 mg/kg b.w., i.p.; Guanfacine at 0.5 mg/kg b.w., i.p.; Guanfacine at 2 mg/kg b.w., i.p.; Significant to 1st day: *P<0.05, **P<0.01,
***P<0.001 (ONE-WAY ANOVA) or significant to control group (water): #P<0.05, ##P<0.01, ###P<0.001 (TWO-WAY ANOVA) or significant to diet-induced
obesity control group (water): ^P<0.05, ^^P<0.01, ^^^P<0.001 (TWO-WAY ANOVA).
doi:10.1371/journal.pone.0141327.g001
Alpha2-Adrenoceptor Ligands and Obesity
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The effect of yohimbine on body weight in rats with high-fat diet-induced
obesity
After 30 days of treatment of obese rats with yohimbine at the dose of 2 mg/kg b.w./day, the
body weight of animals was 8.5% higher than the body weight measured before the first admin-
istration of the drug. After 30 days of treatment, the difference between the body weight in the
diet-induced obesity control group and the group treated with yohimbine at the dose of 2 mg/
kg b.w./day was 3.38% and this was considered insignificant. Even though the rats in this
group gained less weight than those in the diet-induced obesity control group, there was no sta-
tistical difference between these groups, whereas the difference between the controls (receiving
standard food) and the group treated with yohimbine at the dose of 2 mg/kg b.w./day was sig-
nificant (P<0.001). It can be assumed that yohimbine at this dose did not show a significant
anorectic effect. The changes in body weight are shown in Fig 1.
After 30 days of treatment of obese rats with yohimbine at the dose of 5 mg/kg b.w./day, the
body weight of animals was 4.09% higher than the body weight measured before the first
administration of the drug. After 30 days of treatment, the difference between the body weight
in the diet-induced obesity control group and the group treated with yohimbine at the dose of
5 mg/kg b.w./day was 8.17% (P<0.05). The animals treated with yohimbine gained less weight
on the 18th and 21st day of the treatment in comparison with the diet-induced obesity control
group, but there was subsequently no difference between these groups. Taking into consider-
ation the fact that during 30 days of treatment there was no statistical difference between the
controls and the group treated with yohimbine at the dose of 5 mg/kg b.w./day, it can be con-
cluded that yohimbine at this dose showed a minor anorectic effect. The changes in body
weight are shown in Fig 1.
The effect of guanfacine and yohimbine on food and water intake
There was a significant reduction in calorie intake in the group treated with guanfacine at the
dose of 2 mg/kg b.w./day (P<0.01) and the group treated with yohimbine at the dose of 5 mg/
kg b.w./day (P<0.01) in comparison with the diet-induced obesity control group. Moreover, a
significant increase in water consumption in the group treated with guanfacine at the dose of 2
mg/kg b.w./day (P<0.01) and a reduction in the group treated with yohimbine at the dose of 5
mg/kg b.w./day (P<0.05) were observed. The results are shown in Table 3.
Table 3. The effect of studied compounds on body weight, food and water intake.
Diet-induced obesity
control
Yohimbine 2 mg/kg
b.w.
Yohimbine 5 mg/kg
b.w.
Guanfacine 0.5 mg/kg
b.w.
Guanfacine 2 mg/kg b.
w.
Total food intake,
kcal
2532.2 ± 28.76 2218.2 ± 204.33 1945.3 ± 106.32 2081.2 ± 189.53 1676.9 ± 155.21
Total food intake,
g
460.4 ± 5.23 403.3 ± 37.15 353.7 ± 19.33## 378.4 ± 34.46 304.9 ± 28.22##
Total water
intake, ml
831.9 ± 47.50 1041.3 ± 169.70 695.0 ± 40.21# 904.3 ± 77.78 1288.8 ± 107.10##
Food and water intake during 30 days treated using the test compounds in Wistar rats on diet-induced obesity; Treatment: Diet-induced obesity control
group—water; Yohimbine at 2 mg/kg b.w., i.p.; Yohimbine at 5 mg/kg b.w., i.p.; Guanfacine at 0.5 mg/kg b.w., i.p.; Guanfacine at 2 mg/kg b.w., i.p.;
#Significant vs. diet-induced obesity control group, P<0.05;
##Significant vs. diet-induced obesity control group, P<0.01.
doi:10.1371/journal.pone.0141327.t003
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The effect of guanfacine and yohimbine on the amount of intraperitoneal
adipose tissue
Guanfacine injected intraperitoneally at the doses of 0.5 or 2 mg/kg b.w. for 30 days signifi-
cantly reduced the amount of intraperitoneal adipose tissue in comparison with the diet-
induced obese control group (P<0.01). Similarly, yohimbine administered for 30 days at the
dose of 5 mg/kg b.w. showed the same effect (P<0.01). There were no significant changes
between the amount of intraperitoneal adipose tissue in these groups and in the control group
(receiving standard feed). The effect of compounds on the amount of intraperitoneal adipose
tissue is shown in Table 4.
The effect of chronic 30-day treatment with guanfacine and yohimbine
on lipid and carbohydrate profiles and glycerol levels in rats fed a high-
fat diet
The 30-day treatment with yohimbine and guanfacine significantly improved lipid profiles and
decreased the level of triglycerides in plasma in rats fed with high-fat feed. Moreover, both
yohimbine at the doses of 2 mg/kg b.w. and 5 mg/kg b.w., and guanfacine at the dose of 0.5
mg/kg b.w. significantly decreased plasma glucose levels in these animals. In contrast, guanfa-
cine at 2 mg/kg b.w./day significantly increased plasma glucose levels. These results are shown
in Fig 2. Both guanfacine at the dose of 2 mg/kg b.w. and yohimbine at the dose of 5 mg/kg b.
w. significantly increased glycerol levels in plasma in comparison with the levels of glycerol
observed in the plasma of obese control rats. The results (mean ± SEM) were: diet-induced
obese control group 21.1 ± 1.28; guanfacine 28.4 ± 1.81 (t-Student test, P<0.01); yohimbine
33.3 ± 2.51 (t-Student test, P<0.01).
The effect of intraperitoneal administration of studied compounds on
blood pressure and heart rate in normotensive rats
Guanfacine administered intraperitoneally at the dose of 2 mg/kg b.w. significantly increased
blood pressure and caused significant bradycardia. Acute treatment with a dose of 0.5 mg/kg b.
w., i.p. induced a significant increase in blood pressure, but only in the 5th minute after the
administration. Yohimbine administered intraperitoneally at the dose of 5 mg/kg b.w. signifi-
cantly lowered blood pressure and decreased heart rate, whereas at the dose of 2 mg/kg b.w., i.
p. it had no significant effect on blood pressure. The results are shown in Fig 3 and Table 5.
Table 4. The effect of studied compounds on the amount of intraperitoneal adipose tissue.
Control Diet-induced
obesity control
Yohimbine 2 mg/
kg b.w.
Yohimbine 5 mg/
kg b.w.
Guanfacine 0.5
mg/kg b.w.
Guanfacine 2 mg/
kg b.w.
Weight of intraperitoneal
fat tissue [g]
15.5 ± 2.56 28.5 ± 2.28** 23.0 ± 1.49* 14.9 ± 1.30## 17.5 ± 1.14## 14.2 ± 2.59##
Percentage of body
weight
3.90 6.17 5.14 3.49 4.13 3.95
Weight of intraperitoneal fat tissue after 30 days treated using the test compounds in Wistar rats on diet-induced obesity. Treatment: Diet-induced obesity
control group—water; Yohimbine at 2 mg/kg b.w., i.p.; Yohimbine at 5 mg/kg b.w., i.p.; Guanfacine at 0.5 mg/kg b.w., i.p.; Guanfacine at 2 mg/kg b.w., i.p.;
*Significant vs. control group, P<0.05;
**Significant vs. control group, P<0.01;
##Significant vs. diet-induced obesity control group, P<0.01.
doi:10.1371/journal.pone.0141327.t004
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Fig 2. The effect of treatment with guanfacine and yohimbine on lipid and carbohydrate profile. A. TG;
B. Glucose;C. Total cholesterol; D. HDL-cholesterol; E. LDL-cholesterol; Control group—water; Diet-induced
obesity control group—water; Yohimbine at 2 mg/kg b.w., i.p.; Yohimbine at 5 mg/kg b.w., i.p.; Guanfacine at
0.5 mg/kg b.w., i.p.; Guanfacine at 2 mg/kg b.w., i.p.; *Significant vs. control group, #—significant vs. diet-
induced obese control group: *P<0.05, **P<0.01, ***P<0.001 (t-Student).
doi:10.1371/journal.pone.0141327.g002
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Fig 3. The effect on blood pressure after acute treatment with the studied compounds. A: Yohimbine at
2 mg/kg b.w., i.p.; B: Yohimbine at 5 mg/kg b.w., i.p.;C: Guanfacine at 0.5 mg/kg b.w., i.p.; D: Guanfacine at 2
mg/kg b.w., i.p. Mean ± SEM; Significant to time 0: *P<0.05, **P<0.01, ***P<0.001, (ONE-WAY ANOVA)
doi:10.1371/journal.pone.0141327.g003
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The effect of studied drugs on locomotor activity during chronic
treatment in diet-induced obese rats housed in pairs in home cages
Guanfacine at the dose of 2 mg/kg b.w. significantly decreased locomotor activity after single
administration in diet-induced obese rats in comparison with the diet-induced obesity control
group. However, after 29 days of administration of the compound, there was no statistical sig-
nificance. The results are shown in Fig 4.
The effect of guanfacine or yohimbine on core temperature in rats
Both guanfacine and yohimbine significantly decreased core temperature in rats. The effect
was significant for three hours, and after this time we observed an increase in the temperature.
This may be a result of the rapid activation of the mechanisms responsible for maintaining the
temperature homeostasis at the appropriate level. The results are shown in Fig 5. Furthermore,
in rats given guanfacine we observed significant sweating, which may suggest that the thermo-
genesis was intensified.
The effect of chronic 30-day treatment with guanfacine and yohimbine
on cortisol levels in plasma of rats fed a high-fat diet
In obese rats, yohimbine administered for 30 days showed no effect on the level of cortisol in
plasma. In this group, the cortisol plasma level was comparable to that in the control group
(mean ± SEM: t-Student test, 105.4 ± 2.27 for the group treated with yohimbine at 5 mg/kg b.
w./day and 108.0 ± 1.51 for the diet-induced obesity control group) and the glucose level was
significantly lower in comparison with the control group. Given the above data, we can exclude
stress as a factor responsible for weight loss after administration of yohimbine. In contrast,
guanfacine administered at a dose of 2 mg/kg b.w. for 30 days significantly increased cortisol
levels in plasma (mean ± SEM: Student's t-test, 130.3 ± 1.57 for the group treated with
Table 5. Changes in heart rate during 90minutes after intraperitoneal administration of the studied compounds.
A time 0 5 10 15 20 30 40 50 60 70 80 90
mean 281.5 299.8 280.2 261.8 254.2 267.5 260.5 254.7 262.0 286.5 269.2 267.2
SEM 26.49 29.22 37.20 35.95 41.40 31.92 37.21 36.91 27.53 30.62 24.6 24.27
B time 0 5 10 15 20 30 40 50 60 70 80 90
mean 324.0 312.7 284.0 268.8 259.3 255.0 251.5 256.5 251.0 256.5 261.5 246.0
SEM 12.48 15.07 8.97 7.21 6.58 8.20 13.71 18.62 22.35 18.50 21.06 18.72
* * * * * * * *
C time 0 5 10 15 20 30 40 50 60 70 80 90
mean 275.8 270.3 259.3 247.3 238.0 226.0 215.8 209.0 201.8 194.8 194.8 191.5
SEM 23.12 7.48 6.70 6.85 6.31 6.06 6.84 6.40 7.17 6.80 6.80 6.91
** *** *** *** *** *** ***
D time 0 5 10 15 20 30 40 50 60 70 80 90
mean 354.0 286.0 227.8 267.0 264.2 249.0 249.2 236.5 221.3 233.3 230.8 231.8
SEM 8.63 17.40 11.95 11.18 13.88 19.44 18.39 22.67 28.29 23.97 24.29 26.38
* * ** ** ** *** *** *** *** *** ***
A Yohimbine 2 mg/kg b.w.; B Yohimbine 5 mg/kg b.w.; C Guanfacine 0.5 mg/kg b.w.; D Guanfacine 2 mg/kg b.w.; Signifcant vs. 0 time
*P<0.05;
**P<0.01;
***P<0.001, ONE-WAY ANOVA
doi:10.1371/journal.pone.0141327.t005
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guanfacine at the dose of 2 mg/kg b.w./day,  P<0.001) compared with the level in the diet-
induced obesity control group. Moreover, it also significantly raised the level of glucose. Unfor-
tunately, the above results show that this compound at this dose intensified stress in animals.
Lipolysis in vitro
In contrast with guanfacine, yohimbine did not induce a cytotoxic effect at a concentration of
50 μM, as confirmed by a viability assay (PrestoBlue). This assay is an indicator of mitochon-
drial metabolic activity, particularly the mitochondrial electron chain. A decrease in PrestoBlue
fluorescence is an indicator of mitochondrial damage or inactivation of cytosolic and
Fig 4. The effect on locomotor activity after treatment with guanfacine in diet-induced obese rats. After
first administration (A) or after 29th administration (B): Diet-induced obesity control group—water or
Guanfacine at 2 mg/kg b.w., i.p.; Mean ± SEM; Significant to diet-induced obese control group: * P<0.05
(TWO-WAY ANOVA)
doi:10.1371/journal.pone.0141327.g004
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microsomal enzymes. The tested compounds did not exhibit cytotoxic activity in the Toxilight
test, which measures the final stages of cellular death. The test compounds did not affect the
process of lipolysis, but at a concentration of 1 μM they increased the glucose utilization by adi-
pocytes. The results are summarized in Table 6.
Discussion
Guanfacine is a long-acting [13], partial α2-adrenoceptor agonist [11]. It activates α2A-adreno-
ceptors located mainly presynaptically [14]. Guanfacine also has the ability to activate α1-
Fig 5. The effect on core temperature after treatment with guanfacine (A) or yohimbine (B). The
changes in core temperature after a single, intraperitoneal administration of (A) Guanfacine at 2 mg/kg b.w.;
(B) Yohimbine at 5 mg/kg b.w.; Mean ± SEM; Significant to time 0 = 0.5 hour before administration compound
1 (9.15am): * P<0.05, **P<0.01, ***P<0.001, (ONE-WAY ANOVA)
doi:10.1371/journal.pone.0141327.g005
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adrenoceptors [15]. It has been approved by FDA to treat hypertension, and lately to treat con-
duct disorder in children and adolescents [10, 16].
Our study did not confirm the safety of guanfacine in obesity when it was administrated at 2
mg/kg b.w.. Unfortunately, the weight reduction effect caused by guanfacine should be consid-
ered as a symptom of side effects (enhanced stress, decreased spontaneous motility, abnormal
blood pressure and heart rate). However, since there was a significant decrease in body weight
in rats with induced obesity including at a lower dose that does not produce such undesirable
effects, the mechanisms of this phenomenon should be explored.
Our study confirms that guanfacine is a partial α2A- and α2B-adrenoreceptor agonist. It can,
therefore, reduce the release of norepinephrine into the synaptic cleft, thus inhibiting the physi-
ological response to the postsynaptic receptors. However, because it is also a partial agonist, the
stimulation of α2-adrenoreceptors is maintained at a certain level (lower than at the physiologi-
cal stimulation by noradrenalin). Since guanfacine is a long-acting agonist [13], it occupies
adrenoreceptors preventing their rapid stimulation by successive portions of noradrenaline,
which certainly reduces the stimulating action of noradrenaline at α2- and α1-adrenoceptors,
but can also lead to increased noradrenaline binding to β-adrenoreceptors.
Our studies on intrinsic activity confirm that yohimbine is a non-selective antagonist of α2-
adrenoceptors. Some studies suggest that it acts preferentially through α2A-adrenoceptors,
blocking their activation both pre- and postsynaptically [14]. At higher doses, yohimbine also
acts as an α1-adrenoceptor antagonist. By blocking presynaptic α2A-adrenoceptors, yohimbine
increases the release of noradrenaline into the synaptic cleft, but it also blocks postsynaptic
α2A-adrenoceptors and, to a lesser extent, α2B- and α1-adrenoceptors. Therefore, after its appli-
cation the released noradrenaline mainly stimulates β-adrenoceptors, but also to a lesser extent
α2B- and α1-adrenoceptors (depending on dose). These actions are undoubtedly related to its
weight reducing action.
Our research has shown that yohimbine as well as guanfacine showed weight reducing and
anorectic action in a high-fat diet-induced obesity model in rats. Guanfacine shows a much
stronger effect. The effect of yohimbine after administration at 2 mg/kg b.m. was not signifi-
cant, while guanfacine reduced weight at as low a dose as 0.5 mg/kg b.m.. The analysis of the
data concerning the effect on adrenergic receptors shows that this effect is caused by partial
activation of postsynaptic α2B- and α1-adrenoceptors. Another important fact is that both
drugs decrease physiological activation of α2A-adrenoceptors and increase physiological activa-
tion of β-adrenoceptors by noradrenaline. It can be concluded that to achieve a weight reducing
effect, it is essential for drugs acting on adrenergic receptors to reduce, even partially, the
response of α2A-adrenoceptors, and to maintain partial activity of α2B-adrenoceptors.
Table 6. The effect of the tested compounds on cell viability, cell membrane damage, glucose utilization and lipolysis.
Compound Concentration of the compound Cell viability Cell membrane damage Glucose utilization Lipolysis
Yohimbine 50 μM 94.0 ± 2.99 95.3 ± 6.60 95.6 ± 5.60 100.0 ± 2.99
10 μM 103.7 ± 1.46 102.7 ± 2.04 101.3 ± 1.63 100.0 ± 4.48
1 μM 97.0 ± 2.25 109.7 ± 1.47 118.1 ± 0.36 *** 99.3 ± 4.97
Guanfacine 50 μM 82.7 ± 0.72 *** 95.0 ± 8.47 102.0 ± 3.51 100.0 ± 3.53
10 μM 103.0 ± 1.40 92.0 ± 0.65 103.9 ± 0.58 100.0 ± 1.82
1 μM 99.7 ± 3.19 104.7 ± 6.86 112.1 ± 4.76 ** 103.0 ± 4.08
% of control, mean ± SEM;
**P<0.01;
***P<0.001, ONE-WAY ANOVA
doi:10.1371/journal.pone.0141327.t006
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This is in agreement with the results obtained by Janhunsen et al., who showed that by acti-
vating α1-, α2B- and β2-adrenoreceptors noradrenaline reduces calorie intake, and by the acti-
vation of α2A-adrenoceptors increases it [8].
Temperature regulation in brown adipocyte tissue is mediated by the adrenergic system.
Adipose tissue is highly innervated by sympathetic nerves, which activate stimulation when
exposed to cold and food. Since the activation of α2- and β3-adrenoceptors causes opposite
effects, the α2/β3adrenoreceptor ratio is very important not only in thermogenesis but also in
the control of lipolysis in white adipose tissue [17]. The thermogenic action of α2-adrenoceptor
agonists leads to a reduction of thermogenesis [18, 19]. Guanfacine acts in an opposite manner,
i.e. anti-thermogenically [13], which is connected with increasing thermogenesis. In our study,
guanfacine significantly reduced body temperature. Furthermore, we observed intense sweat-
ing in animals which were treated with this drug. This indicates that guanfacine may increase
thermogenesis, which consequently causes weight reduction. It is possible, though, that treat-
ment with a partial agonist such as guanfacine reduces the response of natural agonists, and
causes effects opposite to those of agonists, i.e. antithermogenic and lipolytic effects.
Guanfacine is not a compound which acts typically like other α2-adrenoreceptor agonists,
such as clonidine or xylazine [13, 20]. It has been proven in mice that guanfacine administered
intragastrically at the doses of 0.5 and 2 mg/kg b.w. caused a dose-dependent decrease in appe-
tite and reduced weight gain compared with control animals [13]. In contrast, clonidine
induced an increase in food intake in rats [21]. Furthermore, α2-adrenoreceptor agonists cause
thermogenic action [19], and guanfacine antithermogenic [13]. Moreover, α2-adrenoreceptor
agonists inhibit lipolysis [22], and reduce insulin levels by inhibiting its release [23, 24], which
leads to impaired glucose tolerance and its increased level in blood [24]. Guanfacine causes adi-
pose tissue loss [13], which was also observed in our studies.
It is common knowledge that a decrease in food intake leads to increased lipolysis and
hence to the hydrolysis of triglycerides into free fatty acids and glycerol in adipocyte lipid drop-
lets [25]. In our studies, guanfacine significantly reduced food intake and caused a decrease in
plasma triglyceride and glycerol levels. Therefore, the inhibitory effect of guanfacine on appe-
tite may also be associated with increased lipolysis. Weight reduction after guanfacine treat-
ment begins very quickly. In our studies, the body weight of rats was lower from the first day of
guanfacine administration, and during the next 30 days it remained on a negative balance. In
obese rats, the number of α2-adrenoceptors and the antilipolytic activity in adipocytes is
increased [23]. Because α2- and β3-adrenoceptors coexist on the same fat cell, the ratio of func-
tional α2- and β3-adrenoceptors present in adipose tissue may determine whether fat storage or
release is activated by catecholamines and, therefore, this may play a significant role in regulat-
ing energy balance [26]. Partially blocking the response of noradrenaline at the excessive
amount of α2-adrenoceptors, after treatment with guanfacine, may lead to the activation of
lipolysis, because the response of α2-adrenoceptors is decreased and noradrenaline mainly
stimulates β-adrenoceptors. In vitro studies have not confirmed the effect of guanfacine on
lipolysis. However, we have reported a significant increase in plasma glycerol levels in animals
treated with this drug, which suggests that guanfacine may show a lipolytic activity in vivo.
The reason for increased levels of glucose after guanfacine treatment may be the rapid and
large increase in the release of free fatty acids from adipocytes which reach the liver in too large
quantities, and interfere with its function, which causes glucose intolerance [27]. Some studies
suggest that there is a significant improvement in glucose tolerance and only slight one in insu-
lin secretion in patients with hypertension and diabetes, when treated with guanfacine for one
year [28]. There are also divergent data concerning the effect of guanfacine on plasma choles-
terol levels [29, 30].
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Cortisol is a stress hormone produced by the adrenal glands and is commonly measured to
assess stress [31]. To exclude the possibility that weight loss could be the effect of stress associ-
ated with chronic administration of the drugs, we determined cortisol levels in plasma. In
chronic stress an increase in e.g. corticotropin, cortisol, vasopressin and thyroxin is observed.
The increase in cortisol is connected with a subsequent increase in blood glucose levels and an
increase in appetite. Unfortunately, the plasma cortisol level in animals treated with guanfacine
at the dose of 2 mg/kg b.w. was significantly higher than in the control group. Additionally, an
increase in glucose levels was noticed. These factors clearly demonstrate that guanfacine at this
dose causes stress and its weight reducing properties may be associated with this.
Undoubtedly, the important action against obesity after chronic administration of yohim-
bine is the compensation of impaired lipid profiles and lowering glucose levels, which was con-
firmed in our study. These favorable properties are probably related to the blockade of α1-
adrenoceptors by this drug. It is well known that α1-adrenoceptor antagonists act positively on
lipid and carbohydrate profiles [32].
It has been noticed that, in individuals with an increased risk of developing obesity and dia-
betes, there are too many α2A-adrenoceptors in beta cells in the pancreas, which impairs proper
insulin release and leads to hyperglycemia [33]. Undoubtedly, blocking these receptors by
yohimbine may also lead to a reduction in plasma glucose levels.
The fact is that guanfacine does not block α1-adrenoreceptors, and moreover, at higher
doses it stimulates them. The similar effects on lipid profile after yohimbine and guanfacine
cannot be explained taking into consideration only their effect on this type of adrenergic recep-
tor. There are also divergent data concerning the effect of guanfacine on plasma cholesterol lev-
els [34, 35]. In the world’s literature there are equivocal studies concerning the effect of α1-
adrenoreceptor agonists on lipid and carbohydrate profiles. There are some reports that xyla-
zine induces an increase in plasma glucose level by α1-adrenoreceptor activation [18]. The
exact mechanism by which guanfacine causes hyperglycemia has not yet been determined. Our
present study suggests that this may be connected with stress caused by this drug.
Yohimbine at the dose acting anorexically (5 mg/kg b.w.) showed a hypotensive effect. This
correlates with the findings that the drug blocks α2-adrenoreceptors, and in large doses also
α1-adrenoreceptors. Non-selective α2-adrenoreceptor antagonists possess hypotensive proper-
ties, because they cause vasodilation by blocking α2B-adrenoreceptors and prevent vasospasm
by blocking α2C-adrenoreceptors [22].
The effect of guanfacine on blood pressure confirms that it can activate α2B-adrenoceptors,
and also α1-adrenoceptors. Thus, the regulation of blood pressure at the periphery is regulated
via these receptors [36]. It has been proven that non-selective activation of α2-adrenoceptors
usually leads to a biphasic response in blood pressure: after the short-term pressure increase
phase, the pressure falls below baseline. The activation of α2B-adrenoceptors is responsible for
the increase in blood pressure, while the activation α2A-adrenoceptors induces a long-lasting
phase of drop in blood pressure [22].
Statistically significant bradycardia shown in this study after administration of guanfacine
can confirm the reduction in the response of β1-adrenoceptors to noradrenaline, and it can be
the result of stimulation of the baroreceptor reflex in response to a strong hypertensive effect in
the initial period after administration. In the literature, there are reports of significant, long-
lasting, hypertensive response and long-term bradycardia in patients who have taken guanfa-
cine in large doses [36].
Guanfacine decreased spontaneous activity in the first week of treatment. This effect may be
connected with the reduction of weight. This is an alarming effect of this drug. In the fourth
week, no significant difference in the activity between the studied group and the obese rats in
the control group was observed, which indicates that tolerance to sedation occurs after chronic
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administration of guanfacine. Reduced tolerance can also be caused by abnormalities in blood
pressure and heart rate, and consequently the malaise of animals in the first week of treatment.
There is a risk associated with the chronic use of α2A-adrenoreceptor antagonists. It is well
known that a long-term blockade of the receptors leads to the up-regulation phenomenon—an
increase in their number and sensitivity to physiological agonists [37]. The effectiveness of the
antagonists may therefore be short-term. The reduction of receptor response without the risk
of up-regulation is theoretically possible by using compounds with partial intrinsic activity,
which stimulate the receptor but significantly reduce the response of natural agonists.
Conclusion
This study for the first time clearly indicates the effective anorectic action of guanfacine in
obese rats, and shows that such an effect can be achieved by partial α2A/B-adrenoreceptor ago-
nists. This is the first report that partial α2-adrenoreceptor agonists may possess body weight
reducing activity in the model of obesity.
Yohimbine is less effective in reducing body weight than guanfacine, but it improves lipid
and carbohydrate profiles, and it does not cause such serious side effects.
We believe, however, that α2-adrenoceptor ligands should still be considered potential
drugs reducing body weight, but we should rather look for partial agonists, which will not
show side effects similar to guanfacine and yohimbine.
We suggest, that partial agonists of α2A/B-adrenoreceptors with a very weak intrinsic activity
seem to offer a potential for a good and effective treatment of obesity, with a lower risk of side
effects associated with the cardiovascular system. Of importance is also the lack of affinity for
α1-adrenoceptors. These properties will certainly reduce the occurrence of side effects. How-
ever, it should be emphasized that both the blockade and activation α1-adrenoceptors may
improve therapeutic effects, because the activation leads to a decrease in calorie intake, and the
blockade to the improvement of lipid and carbohydrate profiles.
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